Mangoceuticals (MGRX) Other Accumulated Expenses (2024 - 2026)

Mangoceuticals has disclosed Other Accumulated Expenses across 3 years of filings, most recently posting $147451.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $147451.0, up 469.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $147451.0 (up 469.77% YoY), and the FY2025 annual result was $156642.0, down 58.0% from the prior year.
• Other Accumulated Expenses came in at $147451.0 for Q1 2026 at Mangoceuticals, down from $156642.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $400000.0 in Q2 2024 to a low of $9175.0 in Q2 2025.
• The 3-year median for Other Accumulated Expenses is $158663.0 (2025), against an average of $205978.9.
• Across the five-year window, Other Accumulated Expenses slumped 97.71% in 2025 and surged 469.77% in 2026, its largest moves.
• Mangoceuticals' Other Accumulated Expenses stood at $373000.0 in 2024, then slumped by 58.0% to $156642.0 in 2025, then fell by 5.87% to $147451.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $147451.0 (Q1 2026), $156642.0 (Q4 2025), and $160684.0 (Q3 2025), per Business Quant data.